Drug intelligence / Profile preview

LTG3551

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

LTG3551 is a novel, in-house developed B-cell maturation antigen (BCMA)-targeted CAR T-cell therapy. It is engineered to incorporate two VHH binders, CD8α hinge and transmembrane domains, and 4-1BB and CD3ζ signaling domains. This design aims to provide strong anti-myeloma activity while exhibiting a potentially reduced risk of off-target toxicity, particularly neurotoxicity, by minimizing tonic signaling compared to other BCMA-targeted CAR T-cell therapies like cilta-cel.

Beyond the preview

Go deeper on LTG3551.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTG3551.

Explore the full profile